Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Co-Diagnostics's gross profit for the
three
months ended in Jun. 2026 was €0.11 Mil. Co-Diagnostics's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was €0.27 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Co-Diagnostics's gross profit for the
three
months ended in Jun. 2026 was €0.11 Mil. Co-Diagnostics's Revenue for the
three
months ended in Jun. 2026 was €0.14 Mil. Therefore, Co-Diagnostics's Gross Margin % for the quarter that ended in Jun. 2026 was 72.92%.
Co-Diagnostics had a gross margin of 72.92% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 11 years, the highestGross Margin % of Co-Diagnostics was 88.18%. The lowest was 38.56%. And the median was 77.50%.
Warning Sign:
Co-Diagnostics Inc gross margin has been in long-term decline. The average rate of decline per year is -6.2%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Co-Diagnostics had a gross margin of 72.92% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Co-Diagnostics Gross Profit Related Terms
Co-Diagnostics Gross Profit Historical Data
* Premium members only.
The historical data trend for Co-Diagnostics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:C970 vs HSCS, NVNO, SINT: Gross Profit Comparison
For the Medical Devices subindustry, Co-Diagnostics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.27 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Co-Diagnostics (HAM:C970) has a Gross Profit of €0.27 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Co-Diagnostics and its competitors.
Is Co-Diagnostics' Gross Profit too high?
Co-Diagnostics' current Gross Profit is €0.27 Mil. Overall, Co-Diagnostics has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Gross Profit compare to HSCS and NVNO?
Co-Diagnostics' Gross Profit of €0.27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current Gross Profit is €0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Gross Profit of €0.27 Mil. The stock's GF Value™ is €7.82, compared to a current price of €5.55 — trading 29% below its estimated fair value. The current Gross Profit is €0.27 Mil. Co-Diagnostics' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Gross Profit is €0.27 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued.
The current stock price of €5.55 is trading 29% below its estimated GF Value™ of €7.82.
Key valuation signals for HAM:C970:
Gross Profit: €0.27 Mil
GF Value™: €7.82 vs. price of €5.55 (29% below fair value)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
61GF Score
Get the complete analysis for HAM:C970
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 
